Immunohistochemical staining also showed that the groups receiving CCR2 and CXCR2 antagonists had significantly lower levels of CD68 and myeloperoxidase (MPO) expression, which indicates that the antagonists reduced the number of neutrophils and macrophages in HCC tissues (Fig. 4). Here, CCR2 is linked to hepatocellular carcinoma.